KOSDAQElectronic Components100120

Vieworks

₩27,500▼ 1.08%2026-11-18 close
Market Cap
₩246.7B
Turnover
₩400M
Volume
10K
Shares out.
9M
PER
6.8×
PBR
1.0×
EPS
₩4,175
Dividend Yield
2.43%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩690 per share · Prices as of the 2026-11-18 close

01

Report overview

Machine vision drives profit recovery; Q3 net loss is the watch point

Vieworks' machine vision camera share has passed 30% of sales and operating profit has risen for four straight quarters, but a Q3 2026 net loss attributable to controlling shareholders means earnings durability needs to be checked alongside the recovery.

  1. 1

    Q3 2026 sales were KRW 61.6 billion and operating profit was KRW 11 billion, with operating profit up 154.8% year over year. The company said Q3 sales were the highest for any third quarter.

  2. 2

    Machine vision camera sales reached KRW 18.7 billion in Q3 2026, up 89.7% year over year, lifting their share of total sales to 30.4%. The company attributes this to capital spending on semiconductor packaging inspection equipment.

  3. 3

    Net loss attributable to controlling shareholders was KRW 60.99 million in Q3 2026, a swing from profit a year earlier. Press reports said the company was also in a pre-tax loss, so the line items below operating profit need checking in the annual report.

  4. 4

    Medical X-ray detectors are flat. In 2025 still image detector sales rose 1.5% while video detector sales fell 6.6%, leaving the combined medical X-ray total down 0.8% year over year.

  5. 5

    Operating profit fell 4.1% in 2025, and the debt-to-equity ratio rose from 37.8% in 2022 to 41.5% in 2025. Earnings recovery and the change in capital structure need to be tracked together.

02

Business structure

Vieworks runs two lines: medical imaging and industrial imaging solutions. On the medical side, still image X-ray detectors and video X-ray detectors used in dental and fluoroscopy applications are the core.

Per press reports on the 2025 annual results, still image detector sales were KRW 102.5 billion in 2025, about 43% of total sales, and combined still and video detector sales were about KRW 140.9 billion, roughly 59% of the total.

On the industrial side, machine vision cameras and non-destructive testing (NDT) X-ray detectors make up the rest. The 2025 annual segment figures were KRW 102.5 billion for still image detectors, KRW 38.4 billion for video detectors, KRW 25.9 billion for NDT detectors and KRW 47.2 billion for industrial cameras.

In Q3 2026 the machine vision segment reached KRW 18.7 billion, or 30.4% of sales, with still image detectors at KRW 21.6 billion, video detectors at KRW 9.7 billion, industrial detectors at KRW 6.2 billion and other segments at KRW 5.4 billion, according to the press coverage of the November 2, 2026 preliminary results.

The company describes machine vision as a high-margin segment tied to capital spending on semiconductor packaging inspection equipment. On the detector side it is pushing lightweight FE series and long-format detectors. The other segment includes mammography detectors and digital pathology slide scanners.

On customers, video detectors depend on sales to European dental customers, while still image detectors are supplied to domestic and overseas system customers. Exports to the Americas, Europe and the Middle East account for 90% of industrial X-ray detector sales, according to the company's Q1 2026 release.

Because the company supplies key components to equipment makers, its results follow the capital spending schedules of those customers.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩53.7B₩4.3B8.0%
2025Q4₩68.6B₩8.5B12.4%
2026Q1₩58.2B₩8.8B15.2%
2026Q2₩63.9B₩10.7B16.7%
2026Q3₩61.6B₩11B17.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩237.9B₩43.7B₩26.5B18.3%12.7%37.8%
2023₩220.3B₩18.7B₩14.7B8.5%6.8%35.7%
2024₩222.9B₩22.3B₩21.3B10.0%9.0%36.4%
2025₩239.3B₩21.4B₩22B8.9%8.8%41.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual results show a recovery in sales after a 2023 dip, while operating profit has moved differently. Sales were KRW 237.9 billion in 2022, fell to KRW 220.3 billion in 2023 (down 7.4% year over year), then rose to KRW 222.9 billion in 2024 (up 1.2%) and KRW 239.3 billion in 2025 (up 7.4%).

Sales rose in both 2024 and 2025, and 2025 was the largest year in the 2022 to 2025 period. Operating profit moved the other way. It fell from KRW 43.7 billion in 2022 to KRW 18.7 billion in 2023 (down 57.1%), the smallest year in the period.

It recovered to KRW 22.3 billion in 2024 (up 19.2%) before slipping to KRW 21.4 billion in 2025 (down 4.1%). The operating margin was 18.3% in 2022, 8.5% in 2023, 10.0% in 2024 and 8.9% in 2025. The company attributed the 2025 decline to higher costs from expanding subsidiaries and research spending on new businesses.

Profit attributable to controlling shareholders was KRW 26.5 billion in 2022, KRW 14.7 billion in 2023 (down 44.6%), KRW 21.3 billion in 2024 (up 44.7%) and KRW 22 billion in 2025 (up 3.2%), so it rose in both 2024 and 2025.

Net profit including non-controlling interests followed a different path, at KRW 26.5 billion, KRW 14.8 billion, KRW 21.1 billion and KRW 20.9 billion over the same years. The quarterly pattern changed direction.

Operating profit was KRW 4.3 billion in Q3 2025, then KRW 8.53 billion in Q4 2025, KRW 8.84 billion in Q1 2026, KRW 10.7 billion in Q2 2026 and KRW 11 billion in Q3 2026, rising for four consecutive quarters. Press reports put the operating margin at 15.2% in Q1, 16.7% in Q2 and 17.8% in Q3 2026.

Profit attributable to controlling shareholders was KRW 6.66 billion in Q3 2025, KRW 10.8 billion in Q4 2025, KRW 9.55 billion in Q1 2026 and KRW 16.4 billion in Q2 2026, then turned into a net loss of KRW 60.99 million in Q3 2026.

Over the last four quarters, profit attributable to controlling shareholders totaled KRW 36.7 billion. Operating cash flow went from minus KRW 1.5 billion in 2022 to KRW 23.3 billion in 2023, KRW 35.6 billion in 2024 and KRW 37.2 billion in 2025, so cash generation held up even in the weak profit years.

05

Industry analysis

Vieworks' results reflect two demand flows moving in different directions. On the semiconductor side, AI infrastructure investment and the shift to HBM mass production have increased capital spending on packaging inspection equipment, which the press describes as a boom in semiconductor inspection equipment.

In the 2025 annual results, industrial camera sales rose 11.4% to KRW 47.2 billion, and NDT detector sales grew 43.9% year over year. The company says adoption of 3D CT in battery, semiconductor and PCB inspection is accelerating, and smart factory adoption has lowered the cost of automated X-ray inspection.

On the medical side, growth is slower. Still image detector sales rose only 1.5% in 2025 and video detector sales fell 6.6%. Medical orders follow demand in established uses such as dental and fluoroscopy.

In cycle terms, semiconductor inspection is in an investment expansion phase, while medical imaging depends on product replacement and new product launches.

Vieworks designs its detectors and cameras and supplies them to equipment makers, so results depend on customers' capital spending schedules and product qualification. The company says CE MDR certification across its lineup has strengthened its competitiveness in Europe, according to its Q1 2026 release.

The fact that industrial demand is tied to the semiconductor investment cycle means industry swings can reach reported results quickly.

06

Outlook

The company's plans fall into three areas. First, machine vision demand is tied to semiconductor inspection investment, so AI infrastructure and HBM spending are the key variables, and the company says it will respond actively to semiconductor inspection demand.

Second, it plans to pursue project sales in the North American security market for industrial detectors, according to its Q3 2026 release. Third, it is developing high-resolution detectors that could also be used in HBM stack inspection, according to its Q1 2026 release.

Its bendable detectors have won customers in seven countries within a year of launch, and it plans to strengthen their durability for pipeline and ship inspection. On the medical side, it plans to expand sales of the lightweight FE series and long-format detectors.

In digital pathology, its slide scanners have secured supply in North America and Europe, and it plans to set up sales networks in key overseas hubs. The company also says it is segmenting its lineup from research to clinical diagnostic use, according to Daily Pharm reporting.

Press coverage indicates new businesses still contribute less to total sales than medical X-ray detectors, so how much they offset the medical slowdown is a medium-term checkpoint. The 2026 annual report, the next periodic filing, will give confirmed segment sales for machine vision and medical detectors.

07

Valuation

PER
6.8×
PBR
1.0×
ROE
14.8%
EPS
₩4,175
BPS
₩29,617
Dividend per share
₩690

Valuation has to be read by putting the pace of earnings recovery alongside the share price level. Based on the last four quarters, profit attributable to controlling shareholders totaled KRW 36.7 billion, and the price-to-earnings multiple on that base sits in the single digits.

Because Q3 2026 produced a net loss attributable to controlling shareholders, quarterly multiples are less stable to interpret. The price-to-book ratio is close to net asset value, so the premium over net assets is small. This comes as earnings recover from the 2023 trough.

Cash flow improved before earnings did, with operating cash flow rising from negative in 2022 to KRW 37.2 billion in 2025. The debt-to-equity ratio rose from 37.8% in 2022 to 41.5% in 2025, so the financial headroom has changed too. The 2026 annual report's confirmed full-year profit will be the base for reading the multiples.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Machine vision has become a profit pillar

Machine vision camera sales rose 89.7% year over year to KRW 18.7 billion in Q3 2026, lifting their share of total sales to 30.4%. The company points to higher capital spending on semiconductor packaging inspection equipment. It says operating profit growth outpaced sales growth as the higher-margin segment grew in weight.

Operating margin has moved back up

The operating margin bottomed at 8.5% in 2023, then moved to 10.0% in 2024 and 8.9% in 2025. Quarterly operating profit has risen for four consecutive quarters, and press reports put the operating margin at 15.2% in Q1, 16.7% in Q2 and 17.8% in Q3 2026.

Industrial detectors and new businesses are widening the base

Industrial X-ray detectors grew on demand for 3D CT inspection in batteries, semiconductors and PCBs, as well as sales of bendable detectors for pipeline and ship inspection. The company says its bendable detectors secured customers in seven countries within a year of launch.

Its digital pathology slide scanners have also secured supply in North America and Europe, widening the new business base.

09

Bear factors

Medical X-ray detector growth has stalled

Medical X-ray is the core, accounting for more than half of total sales. Still image detector sales grew only 1.5% in 2025, and video detector sales fell 6.6%. Combined medical X-ray sales declined 0.8% year over year, so slower growth in the core business weighs on overall profitability.

Q3 2026 swung to a net loss for controlling shareholders

Profit attributable to controlling shareholders swung to a KRW 60.99 million net loss in Q3 2026, from a profit a year earlier. Quarterly sales also fell 3.6% from the prior quarter.

Operating profit rose, yet press reports said the company was in a pre-tax loss, so the operating improvement did not carry through to net income.

Earnings volatility and cost burden are large

Operating profit fell 57.1% from KRW 43.7 billion in 2022 to KRW 18.7 billion in 2023, and declined 4.1% in 2025 on higher subsidiary expansion costs and R&D. Q1 2026 sales fell 15.2% from the prior quarter. Past results show that earnings power swings widely with product mix and cost structure.

10

Risk factors

Dependence on the semiconductor investment cycle

Machine vision sales growth rests on AI infrastructure and HBM investment. If that spending slows, equipment demand could fall and quickly feed through to machine vision sales and operating profit.

Quarterly sales swings are already large, with sales falling from KRW 68.6 billion in Q4 2025 to KRW 58.2 billion in Q1 2026.

Export dependence and external variables

Exports to the Americas, Europe and the Middle East make up 90% of industrial X-ray detector sales. Overseas customers' investment timing, local regulations and exchange rates can directly affect sales and profitability. Whether North American security market projects convert as planned is a key check.

Balance sheet and cost burden

The debt-to-equity ratio rose from 37.8% in 2022 to 41.5% in 2025. If subsidiary expansion and new business R&D continue, cost pressure could weigh on profit. The 2025 operating profit decline was attributed to these cost items, making cost control an important issue.

11

What to watch next

  1. January–February 2027 (typical schedule)

    Preliminary Q4 2026 results. Whether operating profit extends its four-quarter rise and how far the Q3 net loss attributable to controlling shareholders recovers in Q4.

  2. By end of March 2027 (annual report filing deadline)

    Confirmed 2026 full-year results and segment sales in the 2026 annual report. Whether machine vision and medical detector shares match the preliminary figures.

  3. First half of 2027 (timing not fixed)

    Project wins in the North American security market and digital slide scanner supply results. Whether new business sales emerge to offset the medical detector slowdown.

  4. Around May 2027 (typical schedule)

    Q1 2027 results. Semiconductor packaging equipment investment will determine whether machine vision sales and the 17.8% operating margin level are sustained.

12

Overall view

Vieworks is growing on machine vision cameras and industrial detectors while medical detectors have stalled. Annual sales rose in both 2024 and 2025 after the 2023 dip, but operating profit recovered from the 2023 trough and then fell again in 2025.

In 2026 quarterly operating profit has risen for four straight quarters, and the company said Q3 2026 sales of KRW 61.6 billion were the highest for any third quarter.

Strengths include semiconductor packaging inspection demand, a growing share of high-margin machine vision sales, and a broader base in industrial detectors and digital pathology.

Weaknesses include the stall in medical X-ray, the Q3 2026 net loss attributable to controlling shareholders, a rising debt-to-equity ratio and dependence on the semiconductor investment cycle.

The direction of profit recovery is clear, but quarterly swings and a pre-tax loss in Q3 mean the durability of earnings still needs confirmation. The next checkpoints are the confirmed results in the 2026 annual report and Q1 2027 earnings.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. newstown.co.kr
  2. industrynews.co.kr
  3. widedaily.com
  4. vegannews.co.kr
  5. newstap.co.kr
  6. newstong.co.kr
  7. venturesquare.net
  8. bokuennews.com
  9. hellot.net
  10. rapportian.com
  11. moneyrecipe.blog
  12. venturesquare.net
  13. newstap.co.kr
  14. venturesquare.net
  15. xrayimaging.vieworks.com
  16. dailypharm.com
  17. sanupin-news.kr
  18. jobkorea.co.kr

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis